Chair - Harold Burstein, MD, PhD                                                        

Dana-Farber Cancer Institute                                       

Boston, Massachusetts, United States                                  

Champalimaud Cancer Center

Lisbon, Portugal

Matthew Ellis, MD, PhD, FRCP

Washington University School of Medicine

St Louis, Missouri, United States

Antonio Llombart Cussac, MD, PhD

Hospital Universitario Arnau de Vilanova

Valencia, Spain

Hope Rugo, MD

University of California, San Francisco

San Francisco, California, United States

This educational activity is specifically designed for non-US medical oncologists, non-US surgical and radiation oncologists, and other non-US healthcare providers interested and/or involved in the treatment of patients with endocrine-responsive breast cancer.

• Identify appropriate treatment strategies for patients with endocrine-responsive metastatic breast cancer in the first-line setting based on current guidelines and clinical trial data


• Discuss the sequencing of hormonal therapies beyond the first-line setting for patients with hormone receptor–positive metastatic breast cancer


• Evaluate treatment options for male patients with endocrine-responsive breast cancer, particularly after progression on selective estrogen receptor modulator therapy


• Examine current data regarding the mechanisms of endocrine resistance and the rationale for therapeutic strategies to overcome resistance


• Assess novel therapeutic approaches for refractory hormone receptor–positive metastatic breast cancer, including new endocrine therapies and combinatorial strategies with targeted agents